Vimta Labs Limited has informed the Exchange about General Updates
VIMTALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
At the 35th Annual General Meeting held on 6th June 2025, shareholders of Vimta Labs approved two key items. First, the company added new objects to its Memorandum of Association, enabling it to undertake Contract Research and Development (CDMO) activities in drug discovery, biotechnology, pharmaceuticals, and related life sciences fields, as well as research in biologics, biosimilars, peptides, and complex generics. Second, the remuneration of three executive directors — Managing Director Ms. Harita Vasireddi, Executive Director Mr. Harriman Vungal, and Executive Director Mr. Satya Sreenivas Neerukonda — was revised as proposed in the AGM notice.
The MOA amendment signals Vimta Labs' strategic intent to expand into high-growth CDMO and biologics/biosimilars segments, which could be positive for long-term growth. The revised remuneration of top executive directors aligns their pay with the company's expanding ambitions and is unlikely to materially impact shareholders in the near term.